Light Therapy Treatment | Phototherapy Applications at MyMedicPlus — Cost, Top Hospitals & Success Rates | MyMedicPlus

Light therapy — also known as phototherapy — encompasses a broad family of medical treatments that harness specific wavelengths of the electromagnetic spectrum to treat a diverse range of medical, dermatological, and psychiatric conditions. Unlike surgical lasers that ablate tissue, most forms of light therapy exert their therapeutic effects through photochemical and photobiological mechanisms: the absorption of photons by biological chromophores (porphyrins, melanin, haemoglobin, water, cytochrome c oxidase) initiates targeted cellular and molecular responses that reduce inflammation, regulate circadian rhythms, destroy pathogens, or stimulate tissue repair.

The therapeutic phototherapy spectrum spans from ultraviolet through visible to near-infrared wavelengths, with each sub-band producing distinct clinical effects:

• Ultraviolet B (UVB, 280–315 nm) — including narrowband UVB (NB-UVB, 311 nm): Immunomodulatory and antiproliferative effects on skin; the most widely used modality for inflammatory skin diseases (psoriasis, vitiligo, eczema, mycosis fungoides).
• Ultraviolet A (UVA, 315–400 nm) with Psoralen (PUVA): Psoralen photosensitiser intercalates with DNA, and UVA irradiation creates covalent crosslinks that inhibit cell division and suppress T-lymphocyte activity.
• Visible Blue Light (407–420 nm): Activates endogenous porphyrins in Cutibacterium acnes (formerly Propionibacterium acnes), generating singlet oxygen that destroys the bacteria responsible for inflammatory acne.
• Visible Red Light (620–700 nm) and Near-infrared (NIR, 700–1100 nm): Stimulates mitochondrial cytochrome c oxidase, increasing ATP production, reducing oxidative stress, and promoting cell proliferation — the basis of low-level laser (light) therapy (LLLT), also known as photobiomodulation (PBM).
• Bright White Light (10,000 lux): Suppresses melatonin secretion and resets circadian phase via retinal photoreceptors; the primary treatment for seasonal affective disorder (SAD) and circadian rhythm sleep disorders.

This guide provides an evidence-based overview of the major light therapy modalities, their indications, and the clinical evidence supporting their use.

Light therapy addresses a remarkably diverse range of conditions across dermatology, psychiatry, neonatology, and rehabilitation medicine. The specific modality, wavelength, and dosing protocol are precisely matched to each indication.

• Seasonal Affective Disorder (SAD): A recurrent major depressive disorder with seasonal (typically autumn-winter) onset, driven by insufficient natural light exposure and resulting phase delay in circadian melatonin and cortisol rhythms. Bright light therapy (10,000 lux) is a first-line evidence-based treatment with response rates of 50–80% in published trials — comparable to antidepressant medication and faster in onset.
• Non-seasonal Depression and Bipolar Depression: Emerging evidence from multiple RCTs supports bright light therapy as an augmentation strategy for non-seasonal depression when administered in the morning, including in bipolar depression with appropriate mood-stabiliser cover.
• Psoriasis: NB-UVB (311 nm) is the standard whole-body phototherapy for moderate-to-severe plaque psoriasis, achieving PASI-75 in 60–70% of patients. PUVA is reserved for NB-UVB-resistant cases.
• Vitiligo: NB-UVB and targeted 308 nm excimer laser are the primary phototherapeutic options for stimulating repigmentation.
• Atopic Dermatitis (Eczema): NB-UVB is second-line for moderate-to-severe eczema not controlled by topical agents; provides immunomodulatory benefit and itch reduction.
• Acne Vulgaris: Blue light (407–420 nm) and combined blue-red light therapy provide antibiotic-free, clinically meaningful reductions in inflammatory acne lesion counts over 4–8 weeks.
• Neonatal Jaundice (Neonatal Hyperbilirubinaemia): Conventional phototherapy using blue-green wavelengths (430–490 nm, 'bili lights') is the primary treatment for neonatal unconjugated hyperbilirubinaemia, photoisomerising bilirubin to water-soluble, readily excreted forms.
• Wound Healing and Musculoskeletal Pain: Low-level laser therapy (LLLT / photobiomodulation) using red (630–660 nm) and NIR (810–980 nm) wavelengths is supported by WALT guidelines for wound healing, neck pain, Achilles tendinopathy, and osteoarthritis of the knee.
• Mycosis Fungoides (Cutaneous T-cell Lymphoma): NB-UVB and PUVA are effective for patch and thin plaque stage CTCL, producing complete responses in the skin in 50–90% of early-stage patients.

Eligibility for light therapy depends on the specific modality and indication. Each form of phototherapy carries distinct eligibility criteria, contraindications, and patient selection considerations.

Narrowband UVB / PUVA (Skin Phototherapy):

• Suitable for adults and children of all Fitzpatrick skin types (I–VI) with appropriate dose calibration to the individual's minimal erythema dose (MED)
• Contraindicated in: lupus erythematosus and other photosensitive dermatoses; use of photosensitising medications (tetracyclines, amiodarone, quinolones, NSAIDs); personal history of melanoma; xeroderma pigmentosum; patients with very extensive prior PUVA exposure (>200 sessions — elevated squamous cell carcinoma risk)
• Relative contraindication in pregnancy: theoretical risk of UV-induced folate photodegradation; NB-UVB during pregnancy may be considered after individualised risk-benefit discussion

Bright Light Therapy (SAD):

• Suitable for most adults; primary contraindication is bipolar disorder without mood stabiliser cover (bright light can precipitate mania/hypomania in susceptible individuals)
• Caution in patients taking photosensitising medications (lithium at high doses, some antidepressants) or with pre-existing retinal conditions (macular degeneration, diabetic retinopathy, retinitis pigmentosa)
• Ophthalmological evaluation recommended before initiating bright light therapy in patients with known retinal disease

Blue Light Acne Therapy:

• Suitable for adults and adolescents with mild-to-moderate inflammatory acne; not indicated for non-inflammatory comedonal acne
• Not suitable as monotherapy for severe cystic acne; best used in combination with topical retinoids or benzoyl peroxide

LLLT / Photobiomodulation:

• Generally safe across patient populations; avoid direct eye exposure (protective eyewear mandatory)
• Not recommended over sites of known or suspected malignancy; avoid during pregnancy over the uterus/abdomen

Light therapy encompasses several distinct modalities, each defined by its wavelength, delivery device, and mechanism of action. Understanding these differences enables appropriate selection for each patient and indication.

• Narrowband UVB Phototherapy (NB-UVB, 311 nm): Delivered in a whole-body phototherapy cabinet (Waldmann, Daavlin), or localised handpiece for targeted areas. Starting dose calibrated to 70% of the patient's MED. Sessions 3 times per week; dose escalated 10–15% per session in absence of significant erythema. Standard course: 20–36 sessions over 8–12 weeks for dermatological conditions. The most widely prescribed phototherapy modality globally.
• PUVA (Psoralen + UVA): Oral methoxypsoralen (8-MOP, 0.4–0.6 mg/kg) taken 1.5–2 hours before UVA irradiation in a UVA cabinet; or topical psoralen paint applied to skin patches 30–60 minutes before UVA exposure. Highly effective for psoriasis and vitiligo; 15–25 sessions for psoriasis clearance. Significant photocarcinogenesis risk with cumulative exposure; reserved for NB-UVB-resistant disease.
• Bright White Light Therapy (10,000 lux) for SAD: Full-spectrum or blue-enriched white light emitted from a medical-grade lightbox at a minimum of 10,000 lux at 50 cm viewing distance. Standard protocol: 30 minutes of morning exposure within 30–60 minutes of waking. Patients should sit in front of the box with eyes open (looking at the light box intermittently, not directly) while reading, eating, or working. Response typically evident within 1–2 weeks. Treatment maintained throughout the at-risk season (autumn to spring). Commercially available devices include Lumie, Beurer, and Philips GoLite BLU.
• Blue Light Therapy for Acne (407–420 nm): Delivered in-clinic (ClearLight, Omnilux Clear, KLERESCA) or via FDA-cleared home devices. Mechanism: Cutibacterium acnes synthesises endogenous porphyrins (predominantly coproporphyrin III), which absorb blue light and generate singlet oxygen that destroys the bacteria. Typical protocol: 2 sessions per week for 4–8 weeks. Combined blue (407–420 nm) + red (633 nm) LED devices (e.g., Omnilux Revive) add anti-inflammatory and sebosuppressive red light effects for synergistic benefit.
• Low-level Laser Therapy / Photobiomodulation (LLLT/PBM): Uses red (630–670 nm) and NIR (810–980 nm) lasers or LEDs at low power densities (typically 10–500 mW/cm²) and radiant exposures (1–10 J/cm²). Mechanism: photon absorption by cytochrome c oxidase in the mitochondrial respiratory chain increases ATP synthesis, reduces reactive oxygen species, and upregulates growth factors and anti-inflammatory mediators. Applications: wound healing, musculoskeletal pain, tendinopathy, lymphoedema, oral mucositis from chemotherapy. WALT (World Association for Laser Therapy) publishes consensus treatment dosage recommendations.
• Neonatal Phototherapy (Blue-green Light, 430–490 nm): Hospital-grade bili lights (fluorescent, LED, or fibreoptic) positioned above the naked neonate at a standard distance. Mechanism: UVB and blue-green light photoconverts insoluble unconjugated bilirubin (4Z,15Z isomer) to water-soluble photoisomers (lumirubin, 4Z,15E bilirubin) that are directly excreted in bile and urine without hepatic conjugation.

Light therapy offers a compelling profile of clinical benefits across its diverse indications, combining meaningful efficacy with favourable tolerability compared to many pharmacological alternatives.

• SAD Bright Light Therapy: Meta-analyses report response rates of 50–80% — comparable to antidepressant medications but with faster onset (1–2 weeks versus 4–6 weeks for SSRIs), no systemic drug interactions, and a side-effect profile limited to mild headache, eyestrain, and nausea that resolve with dose adjustment. Safe for use during pregnancy, when pharmacological antidepressants carry additional teratogenicity concerns.
• NB-UVB Phototherapy: Achieves PASI-75 in 60–70% of psoriasis patients and meaningful repigmentation in 50–70% of vitiligo patients without systemic immunosuppression, making it the preferred treatment for patients who wish to avoid the organ toxicity, infection risk, and cost associated with biological agents.
• Blue Light Acne Therapy: Multiple RCTs demonstrate 50–70% reductions in inflammatory papule and pustule counts after 4–8 weeks of twice-weekly sessions. Provides an effective, antibiotic-free alternative during the global antimicrobial resistance crisis; suitable for patients who cannot use or have failed topical antibiotics or retinoids.
• LLLT / Photobiomodulation: WALT guidelines summarise evidence supporting LLLT for a range of musculoskeletal conditions. Systematic reviews show clinically meaningful pain reduction and functional improvement in neck pain (moderate evidence), Achilles tendinopathy, and knee osteoarthritis. Non-invasive; no significant systemic adverse effects at recommended parameters.
• Neonatal Phototherapy: Highly effective and safe for treating neonatal jaundice; avoids the need for exchange transfusion (a more invasive and risky procedure) in most cases of non-haemolytic neonatal hyperbilirubinaemia. Rapid reduction of serum bilirubin by 1–2 mg/dL within 4–6 hours of initiation.
• Non-pharmacological: All forms of light therapy share the advantage of being drug-free, which is particularly important in pregnancy, paediatrics, and patients with polypharmacy concerns.

The safety profile of light therapy varies by modality. Most forms have an excellent safety record when used correctly, with adverse effects predominantly being mild and manageable.

• NB-UVB and PUVA — Erythema: Sunburn-like reaction is the most common adverse effect of UV phototherapy; indicates excessive dose. Managed by dose reduction at the subsequent session. Severe blistering should not occur with proper MED-based dosing protocols.
• PUVA — Photocarcinogenesis: Long-term PUVA use (cumulative exposure >200 sessions) significantly increases the risk of squamous cell carcinoma and, to a lesser extent, melanoma. This risk is the primary reason NB-UVB has largely replaced PUVA as first-line phototherapy for most indications. PUVA-treated patients require lifelong annual full-body skin examination.
• NB-UVB — Long-term Photodamage: Chronic UV exposure causes cumulative photoageing (photoelastosis, lentigines, telangiectasia). The body surface area-sparing approach of targeted phototherapy (excimer laser) reduces but does not eliminate this concern for whole-body cabinet therapy.
• SAD Light Therapy — Ocular Risks: UV-filtered lightboxes do not transmit UV radiation; the predominant theoretical concern is retinal blue light toxicity with prolonged high-intensity exposure. Use of UV-filtered, medically certified devices eliminates UV risk. Ophthalmological evaluation is recommended for patients with pre-existing retinal pathology before initiating bright light therapy.
• SAD Light Therapy — Psychiatric: Morning bright light can precipitate hypomanic or manic episodes in bipolar disorder. A psychiatrist should supervise light therapy initiation in patients with bipolar I disorder; mood stabiliser cover is essential.
• Blue Light Acne Therapy: Mild erythema and dryness in the treatment area are common and generally self-limiting. No significant systemic adverse effects reported. Avoid use during pregnancy (insufficient safety data for high-intensity blue light devices in this population).
• LLLT / Photobiomodulation: Well-tolerated; no thermal injury at therapeutic doses. Contraindicated directly over the eyes (retinal photosensitivity); avoid over known malignancies; avoid over the gravid uterus. No credible evidence of systemic harm at WALT-recommended treatment parameters.
• Neonatal Phototherapy: Transient side effects include loose stools, mild hyperthermia, skin rash (erythema toxicum), and 'bronze baby syndrome' (in neonates with conjugated hyperbilirubinaemia). Adequate hydration and regular monitoring of temperature and bilirubin levels mitigate these risks.

Follow-up and aftercare requirements for light therapy vary significantly by indication and modality. Key principles for each major application are outlined below.

• NB-UVB Phototherapy (Dermatological): Monitor erythema response at each session and document dose adjustments. Assess PASI or DLQI at 12 sessions and 24 sessions to track treatment response. Patients who achieve clearance should be placed on a tapering maintenance schedule (weekly for 4 weeks, then monthly) to prolong remission. Apply a broad-spectrum SPF 30+ sunscreen to treated areas on sun-exposed days throughout the treatment course and afterwards.
• SAD Bright Light Therapy: Evaluate mood response at 1–2 weeks using a standardised scale (HAM-D, MADRS, or BDI-II). If insufficient response after 2 weeks at standard dose (10,000 lux, 30 min morning), consider extending to 45–60 minutes before escalating to pharmacotherapy. Reduce session duration or switch to afternoon timing if side effects (agitation, insomnia) occur. Maintain light therapy throughout the entire at-risk season (typically October–March in the Northern Hemisphere); abrupt discontinuation can trigger rapid relapse.
• Blue Light Acne Therapy: Assess inflammatory lesion count (papules, pustules) at 4 weeks and 8 weeks. Maintain concurrent topical therapy (retinoid or benzoyl peroxide) between sessions. After achieving a therapeutic response, transitioning to a home LED device for maintenance can be cost-effective.
• LLLT Wound Healing: Document wound dimensions (length x width x depth) and wound bed characteristics (granulation tissue, slough) at each treatment visit. WALT guidelines recommend treatment 3–5 times per week for acute wounds and 2–3 times per week for chronic wounds. Continue until wound closure or plateau of improvement; reassess the treatment strategy at 12 sessions if no meaningful response is apparent.
• Neonatal Phototherapy: Monitor serum bilirubin every 4–6 hours during treatment. Continue phototherapy until bilirubin falls below the threshold for the infant's age and risk category per national clinical guidelines (AAP or NICE). Check for rebound bilirubin rise at 24 hours after discontinuation in infants who received phototherapy in the first 48 hours of life.

The cost of light therapy is highly modality-specific. Home-based options offer significant cost advantages for SAD and acne, while dermatological phototherapy is typically provided in clinical settings with associated session costs.

• SAD Bright Light Therapy: Medical-grade 10,000 lux lightboxes (Lumie Arabica, Beurer TL90, Circadian Optics Lumine) range from USD 40–250 as a one-time purchase. This represents exceptional cost-efficiency compared to pharmacotherapy over a season. NHS England and many European public health systems do not currently reimburse lightboxes, but the low upfront cost makes self-purchase accessible for most patients.
• NB-UVB Phototherapy: In-clinic phototherapy costs vary widely. USA (private pay): USD 50–150 per session (USD 1,500–5,400 for a 36-session course). UK (NHS): provided at no direct cost when referred. India / Thailand: USD 5–20 per session. Home NB-UVB phototherapy units (Daavlin, Kernel) are available for USD 1,500–4,000 and are cost-effective for patients requiring indefinite maintenance therapy; insurance coverage varies by jurisdiction.
• Excimer Laser Phototherapy: Higher per-session cost than NB-UVB but requires fewer sessions (see separate MyMedicPlus articles on excimer laser for psoriasis and vitiligo). USA: USD 150–400 per session. India / Thailand: USD 20–60 per session.
• Blue Light Acne Therapy: In-clinic sessions: USD 40–150 per session in the USA; USD 15–40 in India and Thailand. A full 8-week (16 session) course costs approximately USD 640–2,400 (USA) or USD 240–640 (India/Thailand). Home LED devices cleared for acne treatment (CurrentBody Skin LED Light Therapy Mask, Baby Quasar Pure Rayz) are available for USD 200–400 as a one-time investment.
• LLLT / Photobiomodulation: Clinical LLLT sessions (wound care, physiotherapy): USD 40–120 per session in the USA. Home devices for musculoskeletal pain (handheld NIR laser panels, infrared therapy pads) range from USD 100–500. Professional clinical-grade devices (Theralase, BioFlex) used by physiotherapists and wound care nurses range from USD 10,000–50,000.

Alternative treatments exist for each major indication addressed by light therapy. The appropriate alternative depends on the condition, severity, patient preferences, and access to care.

• For SAD — Alternatives to Bright Light Therapy: Selective serotonin reuptake inhibitors (SSRIs — sertraline, fluoxetine) and SNRIs are first-line pharmacotherapy for SAD and may be preferred for patients with moderate-to-severe depression or those who cannot comply with morning light therapy. Cognitive behavioural therapy adapted for SAD (CBT-SAD) has demonstrated efficacy comparable to light therapy in RCTs and provides more durable protection against seasonal relapse. Melatonin at low doses (0.5 mg), taken in the evening, can assist with phase resetting in patients with circadian delay but is less potent than bright light for depressive symptoms.
• For Psoriasis — Alternatives to NB-UVB: Topical agents (corticosteroids, calcipotriol, calcipotriol-betamethasone combination, tazarotene, roflumilast) for mild-to-moderate localised disease. Systemic agents (methotrexate, ciclosporin, apremilast) for moderate-to-severe disease. Biological agents (IL-17 inhibitors: secukinumab, ixekizumab; IL-23 inhibitors: risankizumab, guselkumab) for moderate-to-severe disease with the highest clearance rates (PASI-90/100).
• For Acne — Alternatives to Blue Light: Topical retinoids (tretinoin, adapalene, tazarotene) are first-line for comedonal and mild inflammatory acne. Topical benzoyl peroxide provides excellent antibacterial and anticomedonal activity without antibiotic resistance risk. Topical antibiotics (clindamycin, erythromycin) combined with benzoyl peroxide. Oral antibiotics (doxycycline, lymecycline) for moderate inflammatory acne. Oral isotretinoin for severe or treatment-resistant acne.
• For Wound Healing — Alternatives to LLLT: Standard moist wound healing (hydrocolloid, foam, alginate, hydrogel dressings). Negative pressure wound therapy (NPWT / VAC therapy) for chronic and complex wounds. Hyperbaric oxygen therapy (HBOT) for diabetic foot ulcers and radiation-induced tissue necrosis. Growth factor therapies (PDGF — becaplermin gel) for diabetic neuropathic ulcers.
• For Neonatal Jaundice — Alternatives to Phototherapy: For mild physiological jaundice, adequate breastfeeding support and monitoring may be sufficient without active treatment. Exchange transfusion is reserved for severe, rapidly rising bilirubin levels unresponsive to phototherapy, or in haemolytic disease with risk of acute bilirubin encephalopathy. Intravenous immunoglobulin (IVIG) reduces the need for exchange transfusion in haemolytic disease due to ABO or Rh incompatibility.